Kidney Failure Prediction: Multicenter External Validation of the KFRE Model in Patients with CKD Stages 3-4 in Peru

Authors:

Bravo-Zúñiga J (0000-0003-2528-6271), nephrologist at Nephrology Department, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Perú.

Chávez-Gómez R (0000-0003-4919-0098), nephrologist at Nephrology Department, Hospital Edgardo Rebagliati Martins, EsSalud, Lima, Perú.

Soto-Becerra P (0000-0001-5332-9254), associated researcher at Universidad Continental, Huancayo, Perú.

Corresponding author:

Correspondence to Percy Soto-Becerra percys1991@gmail.com

Universidad Continental, Huancayo, Perú.

ABSTRACT

Objectives: To externally validate the 4-variable Kidney Failure Risk Equation (KFRE) in the Peruvian population for predicting kidney failure at 2 and 5 years. **Design:** A retrospective cohort study. **Setting:** 17 primary care centers from the Health's Social Security of Peru. **Participants:** Patients older than 18 years, diagnosed with chronic kidney disease (CKD) stage 3a-3b-4 and 3b-4, between January 2013 and December 2017. Patients were followed until they developed kidney failure, died, were lost, or ended the study (December 31, 2019), whichever came first. **Primary and Secondary Outcome Measures:** Performance of the KFRE model was assessed based on discrimination and calibration measures considering the competing risk of death. **Results:** We included 7519 patients in stages 3a-4 and 2,798 patients in stages 3b-4. The estimated cumulative incidence of kidney failure, accounting for competing event of death, at two years and five years was 1.52% and 3.37% in stages 3a-4 and 3.15% and 6.86% in stages 3b-4. KFRE discrimination at 2 and 5 years was high, with Time-Dependent Area Under the Curve (AUC-td) and C-index > 0.8 for all populations. Regarding calibration in-the-large, the Observed-to-Expected (O/E) ratio and the calibration intercept indicated that KFRE underestimates the overall risk at two years and overestimates it at 5-years in all populations. **Conclusions:** The 4-variable KFRE models have good discrimination but poor calibration in the Peruvian population. The model underestimates the risk of kidney failure in the short term and overestimates it in the long term. Further research should focus on updating or recalibrating the KFRE model to better predict kidney failure in the Peruvian context before recommending its use in clinical practice.

Keywords: Prognostic model, chronic kidney disease, chronic kidney replacement therapy, Kidney Failure Risk Equation

SUMMARY BOXES

What is already known on this topic:

- The Kidney Failure Risk Equation (KFRE) has been externally validated in several independent studies worldwide.
- Most of these validations have been conducted in North American, European, and Asian countries.
- There is a notable gap in the literature regarding KFRE validation studies in Latin America, particularly at the primary care level.

What this study adds:

- This study validates the 4-variable KFRE in Peruvian CKD patients, demonstrating good discrimination whilst emphasising the need for recalibration to prevent detrimental patient outcomes.
- Future research should ensure model recalibration, evaluate KFRE's clinical utility, and investigate broader external validation in diverse populations prior to its implementation in clinical practice.

INTRODUCTION

Chronic kidney disease (CKD) is a significant global public health issue with a high economic cost for healthcare systems and a continuously increasing disease burden [1,2]. The prevalence of CKD in the general population worldwide is estimated to be over 10% [2–4]. However, the burden of CKD is more pronounced in low- and middle-income countries, where limited resources and a fragmented healthcare system exacerbate the problem [2,5,6]. In Peru, a middle-income country in Latin America, over 2.5 million adults suffer from some degree of CKD, with estimated prevalences in some regions ranging between 16% and 20% of the general population [7–10].

Timely referral of patients with CKD to nephrologists significantly reduces healthcare costs as CKD progresses to kidney failure and death. In healthcare systems with limited established health networks and few nephrology specialists, early referral is vital [11]. To aid in clinical decision-making, CKD progression risk prediction models provide guidance on when referral to nephrologists is necessary, offer counseling on kidney replacement therapy (KRT) options, and aid in planning vascular access to prevent abrupt and unplanned emergency admissions [12,13]. Accurate short-term predictions are particularly important in situations where establishing accurate individualized risk is critical [14–16]. Conversely, long-term predictions may be more informative in identifying patients who need to remain in primary care for secondary prevention, treatment, and follow-up [14–16].

International guidelines recommend using individualized risk prediction models to inform the appropriate time for nephrologist referral and KRT planning (17–20). However, in Peru, recommendations for referral are primarily based on the isolated or combined use of eGFR, albuminuria, or ACR thresholds [21]. These criteria do not employ individualized risks, which may lead to the unnecesary referral of low-risk patients and the failure to refer high-risk patients [17,22].

The Kidney Failure Risk Equation (KFRE) is an individualized risk prediction equation for CKD patients' progression to kidney failure [23]. Some international guidelines have recommended KFRE for CKD management [14,18,19,24]. The KFRE has an 8-variable and 4-variable version, with the latter being an attractive alternative that requires a few easily accessible variables in the Peruvian health system. However, the predictive error of the models can vary significantly between populations, emphasizing the importance of validating their predictive performance in the population where they are to be applied [25–27].

Unfortunately, the lack of external validation studies of KFRE in the Latin American population, including Peru, has postponed its adoption in local clinical practice.

Therefore, this study aims to validate the 4-variable KFRE model's predictive performance in a large and diverse sample of insured patients assigned to various health establishments of the Social Health Insurance (EsSalud) in Lima, Peru, for predicting the risk of kidney failure at 2 and 5 years.

METHODS

Design, Study Population, and Data Source

We conducted a retrospective cohort study following the Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis guidelines (see TRIPOD checklist in **Supplementary Material**) [27,28] to validate the Kidney Failure Risk Equation (KFRE) model for predicting the risk of kidney failure at 2- and 5-year horizons in patients with chronic kidney disease (CKD).

As part of the EsSalud National Kidney Health Plan, the Rebagliati Healthcare Network established an electronic registry of CKD patients treated at its affiliated health facilities from primary care until tertiary level. We obtained demographic and clinical data from the electronic medical records of the EsSalud Hospital Management System and the Chronic Kidney Disease Management Unit (UMERC) of the Kidney Health Surveillance Subsystem (VISARE) computer application [29].

The study population included patients aged 18 years or older with CKD between January 1, 2013, and December 31, 2017, treated in 17 primary care healthcare centers in the Rebagliati Healthcare Network in Lima, Peru. Lima is the capital of Peru and concentrates most insured patients at national level. We included patients with an estimated glomerular filtration rate (eGFR) between 15 and 60 ml/min/1.73m^2, corresponding to categories 3a, 3b, and 4 of the Kidney Disease Improving Global Outcomes (KDIGO) classification [20], and those who had a recorded quantifiable albumin-to-creatinine ratio (ACR) measurement taken simultaneously with eGFR. The date of ACR measurement was the start point for beginning the follow-up and for predicting the risk of kidney failure using KFRE.

129 We validated the KFRE models in two populations of interest: (i) a broad population of
130 patients with CKD stages 3a, 3b, and 4 (3a-4), such as originally was validated, and (ii) a more
131 specific population with CKD in more advanced stages (3b-4).
132
133 **Patient and Public Involvement**
134 There was no direct patient and public involvement in the design, conduct, or reporting of
135 this study.
136
137 **Sample size**
138 We did not conduct a formal sample size calculation, as we had access to all data collected
139 routinely. Nevertheless, we were cognisant of the unreliability of performance assessment
140 with insufficient sample sizes, particularly in the context of a low number of events.
141 Consequently, we restricted our analysis to clinically relevant subpopulations, ensuring that
142 each group contained a minimum of 100 events and non-events [27]. Given these
143 constraints, we deemed it unreliable to analyse groups 3a, 3b, and 4 separately. Instead, we
144 combined them into subgroups 3a-3b-4 and 3b-4 for the analysis.
145
146 **Validation Model**
147 Tangri et al. developed the KFRE model in Canada in 2011 to predict kidney failure in
148 populations with CKD stages 3 to 5 [23]. The model was later recalibrated based on an
149 extensive meta-analysis that included 31 cohorts from more than 30 countries and over
150 72,000 participants [30]. The 4-variable KFRE includes age, patient sex, eGFR, and ACR
151 collected on the same date for each patient and is an attractive alternative since it requires
152 few variables that are easily accessible in the Peruvian health system. This version has two
153 prediction horizons: short-term at 2 years and long-term at 5 years (equations in **Table S1**).
154
155 **Predictors**
156 The four predictors of the 4-variable KFRE are age (years), sex (male/female), eGFR
157 (ml/min/1.73m^2), and ACR (mg/g) (see **Table S2**). The eGFR was estimated using the 2009
158 CKD Epidemiology Collaboration (CKD-EPI) formula [20,31] (see **Supplementary Methods –**
159 **section 1.3** for details). The health establishments in the Rebagliati Network have
160 standardized care protocols for CKD patients, including laboratory procedures, as part of the
161 Peruvian National Kidney Health Plan. Serum creatinine levels for eGFR estimation were
162 determined from a blood sample. For ACR calculation, urine creatinine and albumin levels
163 were determined by quantitative and automated laboratory tests from a random urine

sample. Qualified personnel verified the preanalytical conditions in each hospital. The urine samples were collected in 10-15 ml bottles and transported between 4 and 8 ºC to the respective laboratory for daily processing. The entire analytical process followed good laboratory and analytical quality control practices. We obtained all data on these variables from UMERC, a computer app designed specifically for this purpose.

Outcome variable

The outcome variable was kidney failure, defined as KRT-treated end-stage renal disease (ESRD), which in Peru comprises the initiation of hemodialysis or peritoneal dialysis indicated by a nephrologist and based on clinical parameters of uremia and eGFR < 15ml/min/1.73m^2.

To estimate the observed risk of kidney failure, we considered the competing event of death without KRT. The data on the date of admission to KRT were obtained from the dialysis database and were verified in the digital clinical history. The date of death until December 31, 2019, was obtained from the National Registry of Identification and Civil Status (RENIEC) of Peru.

Follow-up time

We followed patients until they developed kidney failure, death, or censorship, whichever occurred first. We censored observations until the patient was lost to follow-up or the end of the study (December 31, 2019). We chose to end the study on this date to avoid having data from the pandemic, during which the health system collapsed, kidney care services were affected, and the reliability of the information was altered.

Statistical analysis

Initial data analysis

We performed an initial data analysis to identify implausible extreme values, missing data, and inconsistencies. Plausible extreme data was retained without any transformation in the main analysis. Numerical and categorical variables were described using median (interquartile ranges) and absolute frequencies (percentages), respectively.

Estimate of observed risk

We estimated non-parametric cumulative incidence function (CFI) curves and their 95% confidence intervals (95% CI) using the Aalen-Johansen estimator [32] for kidney failure and considering the competing risk of death without kidney failure.

199

200 ***Predictive Performance of KFRE***

201 We estimated the individual predicted risks of developing kidney failure using the 4-variable
202 KFRE for 2- and 5-year horizons (prediction formulas in **Table S1**). We assessed the
203 performance of the models based on discrimination and calibration measures [27,28]
204 according to TRIPOD guidelines. Additionally, we considered the risk of death without kidney
205 failure and based our analysis workflow on two recently published methodological guides on
206 external validation of prediction models in the presence of competing risks [33,34].

207

208 Discrimination is a relative measure of how well the model distinguishes between patients
209 with or without the condition of interest [34,35]. To assess discrimination, we estimated the
210 truncated concordance index (C-index) at 2- and 5-years for each model and the areas under
211 the ROC time-dependent curves of cumulative sensitivity and dynamic specificity (C/D AUC-
212 td) [36]. A C-index or C/D AUC-td of 1 indicates perfect discrimination, 0.5 indicates no
213 discrimination, and values ≥ 0.8 are generally considered appropriate for prognostic models
214 [35]. We accounted for the competing risk for death without kidney failure by censoring
215 patients who die at infinite, indicating that they may not develop kidney failure in the future
216 [33,34].

217

218 Calibration is a measure that indicates how well the absolute predicted risks agree with the
219 observed risks. These observed risks were estimated using CFI to takte into account the
220 competing risk of death without kidney failure [33,34]. We assessed calibration-in-the-large
221 using the observed to expected results (O/E), a measure of mean calibration, and the
222 calibration intercept, a measure of weak calibration. We also assessed weak calibration
223 through calibration slope. Moderate calibration was assessed inspecting calibration plots.

224

225 We estimated the ratio of observed to expected results (O/E). An O/E indicates perfect global
226 calibration, an O/E > 1 indicates an underestimation of the average risk, and an O/E < 1
227 reveals an overestimated of the average risk. The calibration intercept is another measure
228 that evaluates the average over or underestimation that we estimate in this study. An
229 intercept of 0 indicates perfect agreement between the predicted and observed risk average.
230 An intercept significantly < 0 indicates an overestimation, and an intercept > 0 indicates an
231 underestimation of the risk average. We also estimated the calibration slope. A slope of 1
232 reflects ideal agreement. A slope less than 1 indicates that the predicted risks are too
233 extreme (very high and low), while a slope greater than 1 indicates that the predictions do

not show enough variation. To formally test statistical evidence of miscalibration, we first performed a Wald test of the joint contribution of the intercept and slope, as previously described for calibration models in prediction models [33,34].

Calibration plots allow calibration to be assessed in detail by comparing observed individual risks with those predicted. A curve exactly following the 45º straight line would indicate a perfect situation named strong calibration that is ideal and utopic. A more realistic goal is to assess if the curve is close to the diagonal indicating moderate calibration. We plotted calibration curves estimated by smoothed local linear regression (loess) based on pseudovalues obtained from cumulative incidence estimates that account for the competing risk of death [33,34,37].

Sensitivity analysis

We perform two sensitivity analyses:

1) The same analysis approach after eliminating the extreme values of ACR by winzoring at the 1st and 99th percentiles of the distribution of this variable.

2) A predictive performance analysis ignoring competitive risk. This analysis relied extensively on the methodology described by McLernon DJ et al [37].

General approach

The data preparation and all the analyzes were carried out with the statistical program R version 4.2.1 for Windows 11 x 64 bits. As there were no missing data in critical variables, all analysis were case-complete. Except for the C-index, all the 95% confidence interval (CI) were Wald-type [33,34]. The 95% CI for C-index was obtained using the percentile bootstrap method using 1000 bootstrapped samples [33,34].

RESULTS

Study population

Among the 22,745 patients screened between January 1, 2013, and December 31, 2017, at 17 hospitals within the Rebagliati Healthcare Network in Lima, only 13,890 had complete ACR data, of which 7,519 patients were eligible due to a diagnosis of CKD 3a-4, while 2,798 were eligible for the CKD 3b-4 subgroup (**Figure 1**). All eligible patients had complete data on outcome, age, sex. The number of events of outcome was over 100 in all populations, except for kidney failure at 2-years in patients with CKD 3b-4 stages (n = 88), and thus estimates in this group should be interpreted with caution.

269 *[Figure 1]*

270

271 Within the CKD 3a-4 subgroup, 114 patients developed kidney failure within 2 years, while
272 239 developed kidney failure within 5 years. Moreover, 563 patients died without
273 experiencing kidney failure within 2 years, and 1,400 patients died without experiencing
274 kidney failure within 5 years. Within the CKD 3b-4 group, 88 patients developed kidney
275 failure within 2 years, and 182 developed kidney failure within 5 years, while 300 patients
276 died without experiencing kidney failure within 2 years, and 683 patients died without
277 experiencing kidney failure within 5 years. The median observation time was 4.9 years, and
278 the maximum follow-up was 7.8 years in the CKD 3a-4 group.

279

280 **Table 1** summarizes the baseline characteristics of the study population, and **Supplementary**
281 **Results** provide a breakdown of the study population's characteristics according to kidney
282 failure at 2 and 5 years for CKD 3a-4 (see **Table S3**) and CKD 3b-4 (see **Table S4**), respectively.
283 The numbers of cases of kidney failure at 2 years were low for the subpopulations with
284 stages 3a (n = 26), 3b (n = 36), and 4 (n = 52) (see **Table S5**). Similarly, the 5-year case
285 numbers were low for subpopulations with stages 3a (n = 57), 3b (n = 81), and 4 (n = 101)
286 (**Table S5**). Therefore, evaluating predictive performance in these specific subgroups was
287 unreliable. The distribution of patients in stages 3a-4 and 3b-4 who entered the analysis in
288 each of the 17 health facilities of the EsSalud Rebagliati Network is shown in **Table S6** and
289 **Table S7** of the supplementary material.

290 *[Table 1]*

291

292 **Observed and predicted risk of kidney failure**

293 **Figure 2** displays the observed risk of kidney failure and death without kidney failure for both
294 study populations. The 2- and 5-year observed risks of kidney failure in patients with CKD
295 stages 3a-4 were 1.52% and 3.37%, respectively (**Table S7**). In patients with CKD 3b-4, the 2-
296 and 5-year observed risks of kidney failure were 3.15% and 6.87%, respectively (**Table S8**).
297 The distribution of the 2- and 5-year predicted risk by KFRE are shown in **Figure S1**.

298 *[Figure 2]*

299

300 **KFRE predictive performance**

301 The Kidney Failure Risk Equation (KFRE) demonstrated good discriminatory ability across all
302 time horizons and study populations, as evidenced by C-index and C/D AUC-td values
303 exceeding 0.8 (**Table 2**). In contrast, miscalibration tests shows that data had low

304 compatibility with good calibration of KFRE at all-time horizons and groups (all p-values
305 ≤0.001) proportioning evidence of misscalibration of the model (**Table 2**).
306 *[Table 2]*
307
308 Regarding calibration in the large, for patients with CKD stages 3a-4, the 2-year average
309 observed risk of kidney failure was 1.52%, while the average risk predicted by KFRE was
310 lower at 0.96%, yielding an O/E ratio of 1.57 (95% CI 1.39 to 1.76). This indicates an overall
311 underestimation of the actual 2-year risk of kidney failure by the model. In patients with CKD
312 stages 3b-4, a similar pattern of underestimation of the actual 2-year risk of kidney failure
313 was observed (O/E ratio: 1.33; 95% CI 1.13 to 1.54). In contrast, the imprecision of the
314 calibration intercepts made these estimates less useful for evaluating the calibration in-the-
315 large of KFRE at 2 years for both populations.
316
317 For the 5-year KFRE model, evidence of poor calibration in the large was also observed,
318 although in the opposite direction, suggesting an overprediction. In this case, the O/E ratio
319 was less useful for evaluating the long-term calibration of KFRE due to the high imprecision of
320 its estimates. However, the calibration intercepts revealed that, on average, KFRE
321 overestimated the actual 5-year risk of kidney failure for both the CKD stages 3a-3b-4
322 population (calibration intercept: -0.26; 95% CI -0.45 to -0.07) and the CKD stages 3b-4
323 subgroup (calibration intercept: -0.29; 95% CI -0.48 to -0.1) (**Table 2**).
324
325 KFRE also showed evidence of poor weak calibration. At 2-years, there was statistical
326 evidence of very extreme predictions (i.e., very high and low) for the population with CKD
327 stages 3a-3b-4 (calibration slope: 0.79; 95% CI 0.61 to 0.96) and CKD stages 3b-4 (calibration
328 slope: 0.82; 95% CI 0.6 to 1.03), although the latter with an uncertainty associated with the
329 estimate in the borderline. In the case of the 5-year KFRE, very extreme predictions were also
330 found in both groups, with calibration slopes of 0.75 (95% CI 0.65 to 0.86) for the population
331 with CKD stages 3a-3b-4 and 0.79 (95% CI 0.65 to 0.92) for the population with CKD stages
332 3b-4 (**Table 2**).
333
334 Regarding evidence of poor moderate calibration, the calibration curves (**Figure 3**) revealed
335 that the underestimation of actual risk at 2-years was mainly concentrated in patients with
336 predicted risk less than 0.3-0.4 for both subgroups with CKD stages 3a-4 and CKD stages 3b-4
337 (**Figures 3A** and **3C**). Conversely, the overestimation of the actual risk of renal failure at 5-

338 years mainly occurred in individuals with risk predicted by KFRE greater than 0.2 in both
339 subgroups with CKD stages 3a-4.
340 *[Figure 3]*
341 **Sensitivity analysis: Impact of outliers in ACR**
342 The distribution of the four variables constituting the KFRE equation and the distribution of
343 risks predicted by KFRE are depicted in **Figure S1** and **Figure S2**, respectively. We observed
344 that the ACR variable exhibited very extreme values (**Figure S2 C** and **Figure S2 D**), prompting
345 a sensitivity analysis to evaluate the robustness of our predictive performance assessment
346 after mitigating the influence of these extreme values. Winsorisation of ACR's extreme values
347 was applied at its 1st and 99th percentiles, and risks predicted by KFRE were recalculated
348 using the winsorised ACR variable. Despite observing notable changes in ACR's distribution
349 after winsorisation (**Figure S3**), the distribution of risks predicted by KFRE in the original data
350 did not exhibit discernible alterations (**Figure S4**). Median and mean values of risks predicted
351 by KFRE before and after winsorisation were strikingly similar, as were variability measures
352 such as standard deviation, interquartile range, and range (**Table S10**). As anticipated, the
353 predictive performance of KFRE on the winsorised data closely resembled those obtained on
354 the original data (**Table S11** and **Figure S5**).
355
356 **Sensitivity analysis: Predictive performance assessment ignoring competing risk**
357 We assessed the extent to which the predictive performance results differed when not
358 accounting for competing risks. We found that the 2-year incidence of kidney failure in CKD
359 stages 3a-4, when not considering competing risk, was 1.58%, only slightly higher than when
360 accounting for competing risk (1.52%) (**Fig S6**). At 5 years, these differences become more
361 pronounced but remain relatively small, with a 3.37% incidence when considering competing
362 risk and 4.24% when not considering competing risk. In the CKD stages 3b-4 population, the
363 5-year differences are only about 2% (6.89% when considering competing risk vs. 8.99%
364 when not considering competing risk) (**Fig S6**). Consequently, the assessment of KFRE's
365 predictive performance without considering competing risks also found that KFRE was
366 miscalibrated (**Table S12** and **Fig S6**); however, notably, the magnitude of miscalibration was
367 substantially smaller when ignoring competing risks compared to when competing risks were
368 considered (**Fig S7**).
369
370 **DISCUSSION**
371 **Principal findings**

372 We conducted an independent external validation of the 4-variable KFRE for kidney failure
373 prognosis at 2- and 5-years in patients with CKD at stages 3a-4 and 3b-4 from Peru. Despite
374 showing good discrimination to predict kidney failure, KFRE exhibited poor calibration.
375
376 Poor calibration in the large resulted in the model underestimating the average actual risk of
377 developing kidney failure in the short term (2-years) and overestimating the average actual
378 risk of kidney failure in the long term (5-years) in patientis with CKD stages 3a-4. This pattern
379 of poor calibration was also observed in the subgroup of patients with CKD stages 3b-4. KFRE
380 also had poor weak calibration manifested as very extreme predictions, while poor moderate
381 calibration was evident in the underestimation of actual short-term risk in patients with
382 KFRE-predicted risks below 0.3-0.4 and overestimation of individual long-term risks, primarily
383 in individuals with a KFRE-predicted risk greater than 0.2.
384
385 **Comparison with previous literature**
386 It is noteworthy that the Kidney Failure Risk Equation (KFRE) has been externally validated in
387 several independent external studies worldwide [16,23,30,38–49]. However, the majority of
388 these validations have been conducted in North American [23,30,39,41,43–48] or European
389 countries [16,30,40,49], with more recent validations taking place in other Asian countries
390 [38,42]. Upon conducting a systematic literature search, we were unable to identify any
391 published external validation studies of KFRE specifically within the Latin American
392 population at primary care level. A single study did incorporate a Latin American cohort,
393 comprising Chilean and Brazilian patients; however, extrapolating the study data to the
394 current chronic kidney disease (CKD) patient population presents a challenge, as the cohort's
395 patient recruitment took place between 1996 and 1998 [30]. In the past two decades,
396 significant advancements in CKD management, including diagnostic methods, treatment
397 strategies, and patient care, have contributed to improved patient outcomes. As a result, the
398 external validation results from the Chilean and Brazilian patient cohort [30] may no longer
399 accurately represent current CKD populations in these countries. This emphasises a notable
400 gap in the literature and underscores the need for updated KFRE validation studies in Latin
401 America, ensuring its applicability and accuracy across diverse regional populations.
402
403 In line with prior research, the non-North American versions of the KFRE models at 2- and 5-
404 year intervals exhibited good discrimination in our study and across diverse population
405 groups from countries [16,30,38,40,42,49]. The initial external validation of the non-North
406 American KFRE, a meta-analysis comprising 13 cohorts including Chilean and Brazilian

407 patients [30], reported pooled C-statistics of 0.9 and 0.88 for predicting 2- and 5-year kidney
408 failure, respectively [30]. A more recent study observed lower discrimination values, with C-
409 indexes ranging from 0.76-0.84 for 2-year KFRE and 0.75-0.81 for 5-year KFRE in cohorts from
410 Germany, Italy, the Netherlands, Poland, Switzerland, and the United Kingdom, none of
411 which included Latin American countries [16]. Despite the lower values in the recent study,
412 the discrimination remained good. These findings are consistent with other studies reporting
413 C-index values greater than 0.8 for the non-North American KFRE at 2- and 5-years
414 [38,40,42,49].
415
416 In contrast to discrimination, our study's calibration assessment results differ from the initial
417 study that recalibrated and validated KFRE for non-North American populations [30].
418 Although the few studies that assess calibration of the non-North American version of KFRE
419 have reported poor calibration [33,40,42,49], most primarily focus on moderate calibration
420 using calibration curves, with limited attention given to calibration in the large or weak
421 calibration. Our findings for moderate calibration are in line with previous studies that
422 identified overprediction of kidney failure risk at 5 years [33,40,42,49], particularly in
423 individuals with high predicted risk groups (>0.3 to 0.4) [42,49].
424
425 On the other hand, the 2-year results display greater heterogeneity among existing studies:
426 some cohorts show good calibration [33,42], others overpredict risk in high- and low-risk
427 groups [40]. In our study, we found that KFRE exhibits an opposite pattern of underprediction
428 at 2 years. Regarding calibration in the large, only Ramspek et al. assessed this aspect, finding
429 an overprediction of the average 5-year risk by >10% while observing good calibration in the
430 large at 2 years. This contrasts with our study, which also identified underestimation of the
431 actual average risk by KFRE at 2 years in patients with CKD 3a-4 and CKD 3b-4.
432
433 Differences in severity or stages between the initial study validation and ours could explain
434 these discrepancies. In our study, for example, more than half of patients were classified as
435 having moderate stage of severity of CKD (stage G3a), and we did not include any patients
436 with advanced CKD (stage G5) (**Table 1**). In comparison, Tangri et al. included stage 5 CKD
437 patients, although it is difficult to assess the impact of these differences as Tangri et al. did
438 not report information on the stage distribution of their study population. We also did not
439 observe significant differences in eGFR and albuminuria distributions, recognised markers for
440 kidney failure prognosis [47] in patients with CKD (see **Table S13**). The initial study reported
441 mean (standard devaition) values of 47 ml/min/1.73m^2 (12 ml/min/1.73m^2 ml/min/1.73m^2)

442 for eGFR and a 34% of prevalence of albuminuria for their non-North American population,
443 while our study reported similar values of 46.2 ml/min/1.73m^2 (9.8 ml/min/1.73m^2) and
444 36.5%, respectively (**Table S13**). The actual event risk may also explain the model's
445 miscalibration. Kidney failure incidence rates suggest that risk of kidney failure was lower in
446 the patients with CKD stages 3a-4 of our study (7.4 per 1000 person-years compared to 9.2
447 per 1000 person-years).
448
449 Another explanation for the pattern of overprediction we found in the long term for the KFRE
450 model, especially in advanced CKD populations [43–45], is partly due to not accounting for
451 death without kidney failure as a competing risk [33,34]. This competing risk is crucial for
452 patients with advanced CKD, especially in frail or older populations requiring long-term
453 predictions with more frequent death events [50]. Most existing models censor patients who
454 die, leading to overestimation of the actual risk [51]. Ramspek et al. [16] and Ravani et al.
455 [52] found that KFRE overestimated the actual average risk of terminal CKD by 10-18% and 1-
456 27% at 5 years, respectively, with overestimation increasing over time among high-risk
457 individuals atributable to competing event. By this reason, we considered the competing risk
458 of death without kidney failure in our study. Initial study validating KFRE for non-North
459 American populations also evaluated the impact of competing risk but found no significant
460 differences.
461
462 In our study involving patients with CKD stages 3a-4, 7.5% died without kidney failure at 2
463 years of follow-up, and 20.5% at 5 years (**Table S8**). Conversely, the cumulative incidence of
464 kidney failure was low, with 1.5% at two years and 3.4% at 5 years. This demonstrates the
465 relatively minor impact of competing risk at 2 years, which becomes substantially more
466 significant at 5 years. Even without considering competing risk, the Cox analysis revealed
467 miscalibration, displaying the same patterns as the competing risk analysis, although the
468 degree of miscalibration would have been less pronounced.
469
470 It is important to note that, while differences exist between using Cox and competing risk
471 analyses at the 2-year horizon, these disparities are minimal in our study. In contrast, at 5
472 years, marked differences emerge, with the Cox analysis evidently biasing the performance
473 evaluation. Therefore, we chose to report the competing risk analysis as our primary method
474 and the Cox analysis as secondary. This approach better reflects the increasing impact of
475 competing risk when the incidence of the competing event (death without renal failure)
476 becomes more frequent, as observed in the 5-year assessment.

477

478 **Strengths and limitations of this study**

479 This study boasts several strengths and represents, as far as we know, the second
480 investigation of the Kidney Failure Risk Equation (KFRE) in Latin America, further expanding
481 on the limited research in this region. The only previous study in the region was a meta-
482 analysis that validated the original equation for non-North American populations, which
483 included cohorts from Chile and Brazil [30]. However, these cohorts are no longer current, as
484 they date back to 1996-1998 [30]. By providing the first external validation of KFRE in Peru,
485 this study fills a critical gap in the literature and offers valuable insights into the applicability
486 of KFRE in a contemporary Latin American context. Drawing from a retrospective cohort of
487 over 7,000 patients across 17 primary and secondary care EsSalud health establishments in
488 Lima, the capital city accounting for a third of Peru's population, the findings have a certain
489 degree of generalisability. The results are particularly relevant for EsSalud-insured patients in
490 Lima, who make up a significant proportion of chronic kidney disease (CKD) patients in the
491 country.

492

493 Employing robust statistical methods and sound analytical techniques, the study
494 appropriately assesses the performance of KFRE in predicting kidney failure while considering
495 the competing risk of death without kidney failure. This approach helps avoid overestimation
496 of the observed risk and reduces bias in performance assessment, as opposed to solely
497 relying on Cox methods, which were originally considered in the study protocol [33,34,50,53].
498 The decision to use this competing risk approach as a primary analysis, with Cox methods
499 employed in a sensitivity analysis, was informed by contemporary evidence demonstrating
500 that accounting for competing risks offers a less biased and more accurate estimation of the
501 actual kidney failure risks [33,52]. As such, this study adheres to best practices in the field
502 and contributes essential knowledge regarding KFRE's performance in Peru and Latin America
503 more broadly.

504

505 Although our study presents valuable findings; it is important to acknowledge several
506 limitations. Firstly, we utilized secondary data routinely recorded by multiple evaluating
507 clinicians across 17 healthcare centers in Lima. On one hand, using routine clinical data has
508 the advantage of potentially reflecting the model's performance more accurately in real-
509 world clinical practice. However, despite standardization of laboratory measurements as part
510 of the National Kidney Program in Peru, clinical registries are inherently susceptible to errors
511 in data recording, thereby introducing the potential for measurement error.

512

513 Another limitation stems from our use of RRT initiation as an indicator of kidney failure in
514 patients. This approach carries the risk of misclassification for patients who may have opted
515 for conservative management. Nevertheless, it is worth noting that conservative
516 management is relatively rare in Peru. Furthermore, access to RRT for EsSalud beneficiaries in
517 Lima is fully covered by EsSalud, which bears the entire cost reducing the risk of not access to
518 RRT, specially in Lima. These factors imply that the risk of bias might be reduced;
519 nevertheless, we still regard this as a significant limitation that should be appropriately
520 addressed in future prospective studies.
521

522 Lastly, although the similarities among EsSalud service networks in Lima may support the
523 notion that our findings could be generalizable to other networks in the city, it is crucial to
524 recognize that Lima is not representative of the entirety of Peru, and EsSalud is not the sole
525 healthcare system in the country [54,55]. Significant disparities exist in healthcare services
526 provided outside Lima and between different healthcare systems, such as Comprehensive
527 Health Insurance and the Health of the Armed and Police Forces. These variations may
528 influence KFRE's predictive performance, necessitating specific external validation studies in
529 these populations due to the distinct differences among Peruvian health subsystems.
530

531 **Implications for clinical practice**

532 The observed differences in KFRE model performance among various cohorts highlight the
533 necessity of broadening external validation across diverse populations and settings [25].
534 Although our study demonstrates KFRE's capacity to effectively discriminate between
535 patients who will develop kidney failure at 2 and 5 years, it also reveals the model's
536 shortcomings in accurately predicting individual risks, underestimating them in the short
537 term and overestimating them in the long term. Sole reliance on KFRE's discrimination ability
538 may have adverse implications for patients. Given our findings that short-term
539 overestimation of kidney failure risk occurs in patients with low predicted risk and long-term
540 underestimation occurs in those with high predicted risk, this pattern of poor moderate
541 calibration could result in detrimental patient outcomes.
542

543 For example, overestimation of risk (overprediction) in patients with a lower true long-term
544 progression risk may lead to unnecessary referrals for dialysis preparation, provoking
545 unwarranted anxiety for patients and potentially increasing the risk of death from non-kidney
546 failure causes, such as preventable cardiovascular events, if the patient had remained at the

primary care level. In contrast, underestimation of risk (underprediction) in patients with a higher true short-term progression risk due to a miscalibrated KFRE might cause unnecessary delays in their referral and preparation for dialysis.

Future research

Future research should focus on ensuring model recalibration for clinically relevant populations in Peru, considering our findings that reveal KFRE miscalibration for EsSalud patients in Lima. It is imperative that external validation and recalibration assessments expand to a national level, encompassing the broader EsSalud population. This evidence could expedite the incorporation of KFRE into EsSalud's clinical practice guidelines.

In concurrence with the recommendations previously put forward by Ramspek et al. [33], it is essential to examine the influence of patient mix heterogeneity on model performance, such as through regional comparisons within Peru. This will help in understanding KFRE's limitations and proposing specific recalibrations to enhance performance at the local level. When conducting external validation and recalibration for these new populations, researchers should account for competitive risk. Further studies should assess KFRE's clinical utility and determine optimal risk thresholds, if necessary, for informed decision-making while taking clinical relevance into account. Moreover, research should evaluate the impact of KFRE use on significant patient and healthcare system outcomes, including dialysis complications, mortality, and emergency admissions, among others. Notably, these investigations should be conducted within the context of clinical trials.

Conclusions

The KFRE model using four variables demonstrated good discrimination at 2 and 5 years for patients with CKD stages 3a-3b-4 and CKD stages 3b-4. However, our study also found that the KFRE model was miss calibrated, underestimating short-term risks, and overestimating long-term risks. Despite its great discriminative capacity, the KFRE model should be recalibrated before being recommended for use in clinical practice guidelines for the Peruvian population. In light of this evidence, Latin American countries should consider externally validating and recalibrating this model before recommending its use in clinical practice.

CONTRIBUTORS

JBZ served as the principal investigator, conceived the study concept, developed the proposal, contributed to the study design, coordinated the project, and participated in drafting the manuscript. RCG co-authored the proposal, contributed to the study design, oversaw data acquisition and preprocessing, and assisted in drafting the manuscript. PSB co-authored the propoposal, contributed to the study design, was responsible for cleaning the raw data, conducting the analysis, and preparing the manuscript. JBZ and PSB serve as guarantors, ensuring the integrity of the study. The corresponding author attests that all listed authors meet authorship criteria and that no others meeting the criteria have been omitted. The authors would like to acknowledge the methodological advisoring of the Instituto de Evaluación de Tecnologías en Salud e Investigación – IETSI, during the initial stages of the project, through its Personalised Mentoring Programme 2020, in the development of this study.

FUNDING

This study was entirely self-funded by the authors and did not receive any external financial support.

ETHICAL APPROVAL

The Research Ethics Committee of the Edgardo Rebagliati National Hospital approved this study (575-GRPR-ESSALUD-2021). Because all the data from clinical registries were anonymized before being processed for the research, the ethics committee accepted the waiver of informed consent from the patients.

COMPETING INTEREST

JBZ and RCG are full-time employees of EsSalud, and PSB has received consultancy fees from EsSalud. However, the authors affirm that their respective affiliations with EsSalud have not influenced any aspect of the study, including study design, data collection, analysis, interpretation, or manuscript preparation. The authors declare that there are no other competing interests or potential conflicts of interest related to the content of this manuscript.

DATA SHARING

The analysis code essential for the replication of study findings can be accessed at this link: https://github.com/psotob91/kfre-ckd-reba-peru. As per the privacy policies of EsSalud, the

minimal data set is not open to public access. However, we are amenable to providing the anonymised data upon receipt of a reasonable request directed to the corresponding author (percys1991@gmail.com).

TRANSPARENCY DECLARATION

JBZ and PSB, as the manuscript's guarantors, affirm that the manuscript presents an honest, accurate, and transparent account of the study reported. They confirm that no significant aspects of the study have been omitted, and any discrepancies from the planned study have been duly explained.

627 **REFERENCES**

628 1 Xie Y, Bowe B, Mokdad AH, *et al.* Analysis of the Global Burden of Disease study
629 highlights the global, regional, and national trends of chronic kidney disease
630 epidemiology from 1990 to 2016. *Kidney Int* 2018;**94**:567–81.
631 doi:10.1016/j.kint.2018.04.011

632 2 Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney Int Suppl*
633 2022;**12**:7–11. doi:10.1016/j.kisu.2021.11.003

634 3 Hill NR, Fatoba ST, Oke JL, *et al.* Global Prevalence of Chronic Kidney Disease - A
635 Systematic Review and Meta-Analysis. *PloS One* 2016;**11**:e0158765.
636 doi:10.1371/journal.pone.0158765

637 4 Sundström J, Bodegard J, Bollmann A, *et al.* Prevalence, outcomes, and cost of chronic
638 kidney disease in a contemporary population of 2·4 million patients from 11 countries:
639 The CaReMe CKD study. *Lancet Reg Health – Eur* 2022;**20**.
640 doi:10.1016/j.lanepe.2022.100438

641 5 Stanifer JW, Muiru A, Jafar TH, *et al.* Chronic kidney disease in low- and middle-income
642 countries. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc*
643 2016;**31**:868–74. doi:10.1093/ndt/gfv466

644 6 Suriyong P, Ruengorn C, Shayakul C, *et al.* Prevalence of chronic kidney disease stages 3–
645 5 in low- and middle-income countries in Asia: A systematic review and meta-analysis.
646 *PLOS ONE* 2022;**17**:e0264393. doi:10.1371/journal.pone.0264393

647 7 Francis ER, Kuo C-C, Bernabe-Ortiz A, *et al.* Burden of chronic kidney disease in resource-
648 limited settings from Peru: a population-based study. *BMC Nephrol* 2015;**16**:114.
649 doi:10.1186/s12882-015-0104-7

650 8 Bravo-Zúñiga J, Gálvez-Inga J, Carrillo-Onofre P, *et al.* Early detection of chronic renal
651 disease: coordinated work between primary and specialized care in an ambulatory renal
652 network of Peru. *J Bras Nefrol Orgao Of Soc Bras E Lat-Am Nefrol* 2019;**41**:176–84.
653 doi:10.1590/2175-8239-JBN-2018-0101

654 9 Herrera-Añazco P, Taype-Rondan A, Lazo-Porras M, *et al.* Prevalence of chronic kidney
655 disease in Peruvian primary care setting. *BMC Nephrol* 2017;**18**:246.
656 doi:10.1186/s12882-017-0655-x

657 10 Loza Munarriz CA, Ramos Muñoz WC. *Análisis de la situación de la enfermedad renal*
658 *crónica en el Perú, 2015*. 1ª. Lima 11, Peru: : Dirección General de Epidemiología,
659 Ministerio de Salud del Perú 2016. https://www.gob.pe/institucion/minsa/informes-
660 publicaciones/285012-analisis-de-la-situacion-de-la-enfermedad-renal-cronica-en-el-
661 peru-2015

662 11 Martínez-Castelao A, Soler MJ, Górriz Teruel JL, *et al.* Optimizing the timing of
663 nephrology referral for patients with diabetic kidney disease. *Clin Kidney J* 2021;**14**:5–8.
664 doi:10.1093/ckj/sfaa125

665 12 Lerner B, Desrochers S, Tangri N. Risk Prediction Models in CKD. *Semin Nephrol*
666 2017;**37**:144–50. doi:10.1016/j.semnephrol.2016.12.004

667 13 Wojciechowski P, Tangri N, Rigatto C, *et al.* Risk Prediction in CKD: The Rational
668 Alignment of Health Care Resources in CKD 4/5 Care. *Adv Chronic Kidney Dis*
669 2016;**23**:227–30. doi:10.1053/j.ackd.2016.04.002

670 14 Eckardt K-U, Bansal N, Coresh J, *et al.* Improving the prognosis of patients with severely
671 decreased glomerular filtration rate (CKD G4+): conclusions from a Kidney Disease:
672 Improving Global Outcomes (KDIGO) Controversies Conference. *Kidney Int*
673 2018;**93**:1281–92. doi:10.1016/j.kint.2018.02.006

674 15 Chapter 2: Definition, identification, and prediction of CKD progression. *Kidney Int Suppl*
675 2013;**3**:63–72. doi:10.1038/kisup.2012.65

676 16 Ramspek CL, Evans M, Wanner C, *et al.* Kidney Failure Prediction Models: A
677 Comprehensive External Validation Study in Patients with Advanced CKD. *J Am Soc*
678 *Nephrol JASN* 2021;**32**:1174–86. doi:10.1681/ASN.2020071077

679 17 Oliva-Damaso N, Delanaye P, Oliva-Damaso E, *et al.* Risk-based versus GFR threshold
680 criteria for nephrology referral in chronic kidney disease. *Clin Kidney J* 2022;**15**:1996–
681 2005. doi:10.1093/ckj/sfac104

682 18 *Chronic kidney disease: assessment and management*. London: : National Institute for
683 Health and Care Excellence (NICE) 2021.
684 http://www.ncbi.nlm.nih.gov/books/NBK574714/ (accessed 12 Jan 2023).

685 19 Farrington K, Covic A, Aucella F, *et al.* Clinical Practice Guideline on management of older
686 patients with chronic kidney disease stage 3b or higher (eGFR <45 mL/min/1.73 m2).
687 *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc* 2016;**31**:ii1–66.
688 doi:10.1093/ndt/gfw356

689 20 Levin A, Stevens PE, Bilous RW, *et al.* Kidney disease: Improving global outcomes (KDIGO)
690 CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and
691 management of chronic kidney disease. *Kidney Int Suppl* 2013;**3**:1–150.
692 doi:10.1038/kisup.2012.73

693 21 Bravo-Zúñiga J, Hinostoza-Sayas J, Goicochea Lugo S-, *et al.* Guía de práctica clínica para
694 el tamizaje, diagnóstico y manejo de la enfermedad renal crónica en estadios 1 al 3 en el
695 Seguro Social del Perú (EsSalud). *Acta Médica Peru* 2020;**37**:518–31.
696 doi:10.35663/amp.2020.374.1843

697 22 Bhachu HK, Fenton A, Cockwell P, *et al.* Use of the kidney failure risk equation to inform
698 clinical care of patients with chronic kidney disease: a mixed-methods systematic review.
699 *BMJ Open* 2022;**12**:e055572. doi:10.1136/bmjopen-2021-055572

700 23 Tangri N, Stevens LA, Griffith J, *et al.* A predictive model for progression of chronic kidney
701 disease to kidney failure. *JAMA* 2011;**305**:1553–9. doi:10.1001/jama.2011.451

702 24 Chan CT, Blankestijn PJ, Dember LM, *et al.* Dialysis initiation, modality choice, access, and
703 prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO)
704 Controversies Conference. *Kidney Int* 2019;**96**:37–47. doi:10.1016/j.kint.2019.01.017

705 25 Ramspek CL, Jager KJ, Dekker FW, *et al.* External validation of prognostic models:
706 what, why, how, when and where? *Clin Kidney J* 2021;**14**:49–58. doi:10.1093/ckj/sfaa188

707 26 Bleeker SE, Moll HA, Steyerberg EW, *et al.* External validation is necessary in prediction
708 research: a clinical example. *J Clin Epidemiol* 2003;**56**:826–32. doi:10.1016/s0895-
709 4356(03)00207-5

710 27 Moons KGM, Altman DG, Reitsma JB, *et al.* Transparent Reporting of a multivariable
711 prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and
712 elaboration. *Ann Intern Med* 2015;**162**:W1-73. doi:10.7326/M14-0698

713 28 Collins GS, Reitsma JB, Altman DG, *et al.* Transparent reporting of a multivariable
714 prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD Statement.
715 *BMC Med* 2015;**13**:1. doi:10.1186/s12916-014-0241-z

716 29 Oficina de Gestión y Desarrollo de Salud renal - EsSalud. Directiva de la Gerencia Central
717 de Prestaciones de Salud N° 03-GCPS-ESSALUD-2012: Subsistema de Vigilancia de Salud
718 Renal (VISARE) - ESSALUD. 2012.

719 30 Tangri N, Grams ME, Levey AS, *et al.* Multinational Assessment of Accuracy of Equations
720 for Predicting Risk of Kidney Failure: A Meta-analysis. *JAMA* 2016;**315**:164–74.
721 doi:10.1001/jama.2015.18202

722 31 Levey AS, Stevens LA, Schmid CH, *et al.* A New Equation to Estimate Glomerular Filtration
723 Rate. *Ann Intern Med* 2009;**150**:604–12.

724 32 Aalen OO, Johansen S. An Empirical Transition Matrix for Non-Homogeneous Markov
725 Chains Based on Censored Observations. *Scand J Stat* 1978;**5**:141–50.

726 33 Ramspek CL, Teece L, Snell KIE, *et al.* Lessons learnt when accounting for competing
727 events in the external validation of time-to-event prognostic models. *Int J Epidemiol*
728 2022;**51**:615–25. doi:10.1093/ije/dyab256

729 34 Geloven N van, Giardiello D, Bonneville EF, *et al.* Validation of prediction models in the
730 presence of competing risks: a guide through modern methods. *BMJ* 2022;**377**:e069249.
731 doi:10.1136/bmj-2021-069249

732 35 Riley RD, Windt D van der, Croft P, editors. *Prognosis research in healthcare: concepts,*
733 *methods, and impact*. First edition. Oxford: : Oxford University Press 2019.

734 36 Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in
735 medical research: current methods and applications. *BMC Med Res Methodol*
736 2017;**17**:53. doi:10.1186/s12874-017-0332-6

737 37 McLernon DJ, Giardiello D, Van Calster B, *et al.* Assessing Performance and Clinical
738 Usefulness in Prediction Models With Survival Outcomes: Practical Guidance for Cox
739 Proportional Hazards Models. *Ann Intern Med* 2023;**176**:105–14. doi:10.7326/M22-0844

740 38 Wang Y, Nguyen FNHL, Allen JC, *et al.* Validation of the kidney failure risk equation for
741 end-stage kidney disease in Southeast Asia. *BMC Nephrol* 2019;**20**:451.
742 doi:10.1186/s12882-019-1643-0

743 39 Thanabalasingam SJ, Iliescu EA, Norman PA, *et al.* Independent External Validation and
744 Comparison of Death and Kidney Replacement Therapy Prediction Models in Advanced
745 CKD. *Kidney Med* 2022;**4**:100440. doi:10.1016/j.xkme.2022.100440

746 40 Major RW, Shepherd D, Medcalf JF, *et al.* The Kidney Failure Risk Equation for prediction
747 of end stage renal disease in UK primary care: An external validation and clinical impact
748 projection cohort study. *PLoS Med* 2019;**16**:e1002955.
749 doi:10.1371/journal.pmed.1002955

750 41 Hundemer GL, Tangri N, Sood MM, *et al.* Performance of the Kidney Failure Risk
751 Equation by Disease Etiology in Advanced CKD. *Clin J Am Soc Nephrol CJASN*
752 2020;**15**:1424–32. doi:10.2215/CJN.03940320

753 42 Kwek JL, Pang HQJ, Li H, *et al.* Validation of the kidney failure risk equation in predicting
754 the risk of progression to kidney failure in a multi-ethnic Singapore chronic kidney
755 disease cohort. *Singapore Med J* 2022;**63**:313–8. doi:10.11622/smedj.2020170

756 43 Peeters MJ, van Zuilen AD, van den Brand JAJG, *et al.* Validation of the kidney failure risk
757 equation in European CKD patients. *Nephrol Dial Transplant Off Publ Eur Dial Transpl*
758 *Assoc - Eur Ren Assoc* 2013;**28**:1773–9. doi:10.1093/ndt/gft063

759 44 Potok OA, Nguyen HA, Abdelmalek JA, *et al.* Patients,' Nephrologists,' and Predicted
760 Estimations of ESKD Risk Compared with 2-Year Incidence of ESKD. *Clin J Am Soc Nephrol*
761 *CJASN* 2019;**14**:206–12. doi:10.2215/CJN.07970718

762 45 Whitlock RH, Chartier M, Komenda P, *et al.* Validation of the Kidney Failure Risk Equation
763 in Manitoba. *Can J Kidney Health Dis* 2017;**4**:2054358117705372.
764 doi:10.1177/2054358117705372

765 46 Grams ME, Sang Y, Ballew SH, *et al.* Predicting timing of clinical outcomes in
766 patients with chronic kidney disease and severely decreased glomerular filtration rate.
767 *Kidney Int* 2018;**93**:1442–51. doi:10.1016/j.kint.2018.01.009

768 47 Naranjo FS, Sang Y, Ballew SH, *et al.* Estimating Kidney Failure Risk Using Electronic
769 Medical Records. *Kidney360* 2021;**2**:415–24. doi:10.34067/KID.0005592020

770 48 Bundy JD, Mills KT, Anderson AH, *et al.* Prediction of End-Stage Kidney Disease Using
771 Estimated Glomerular Filtration Rate With and Without Race: A Prospective Cohort
772 Study. *Ann Intern Med* 2022;**175**:305–13. doi:10.7326/M21-2928

773 49 Marks A, Fluck N, Prescott GJ, *et al.* Looking to the future: predicting renal replacement
774 outcomes in a large community cohort with chronic kidney disease. *Nephrol Dial*
775 *Transplant* 2015;**30**:1507–17. doi:10.1093/ndt/gfv089

776 50 Li L, Yang W, Astor BC, *et al.* Competing Risk Modeling: Time to Put it in Our Standard
777 Analytical Toolbox. *J Am Soc Nephrol* 2019;**30**:2284–6. doi:10.1681/ASN.2019101011

778 51 Wolkewitz M, Cooper BS, Bonten MJM, *et al.* Interpreting and comparing risks in the
779 presence of competing events. *BMJ* 2014;**349**:g5060. doi:10.1136/bmj.g5060

780 52 Ravani P, Fiocco M, Liu P, *et al.* Influence of Mortality on Estimating the Risk of Kidney
781 Failure in People with Stage 4 CKD. *J Am Soc Nephrol JASN* 2019;**30**:2219–27.
782 doi:10.1681/ASN.2019060640

783 53 Mehta P, Dhapte V, Kadam S, *et al.* Contemporary acupressure therapy: Adroit cure for
784 painless recovery of therapeutic ailments. *J Tradit Complement Med* 2017;**7**:251–63.
785 doi:10.1016/j.jtcme.2016.06.004

786 54 Alcalde-Rabanal JE, Lazo-González O, Nigenda G. [The health system of Peru]. *Salud*
787 *Publica Mex* 2011;**53 Suppl 2**:s243-254.

788 55 F S-M. [The national health system in Peru]. *Rev Peru Med Exp Salud Publica*
789 2014;**31**.https://pubmed.ncbi.nlm.nih.gov/25597729/ (accessed 23 Nov 2022).

790

791

792

793

794 **Table 1. Baseline characteristics of the study population according to CKD stages.**

Characteristic	CKD Stages 3a-3b-4 (n = 7,519)	CKD Stages 3b-4 (n = 2,798)
Sex		
Female	4,107 (54.6%)	1,398 (50.0%)
Male	3,412 (45.4%)	1,400 (50.0%)
Age (years)		
Mean (SD)	74.0 (10.2)	75.6 (10.6)
Median (IQR)	75.0 (68.0 - 81.0)	77.0 (70.0 - 83.0)
Range	23.0 - 97.0	23.0 - 97.0
Hypertension	4,486 (59.7%)	1,636 (58.5%)
Diabetes Mellitus	1,845 (24.5%)	674 (24.1%)
Persistent albuminuria categories		
A1	4,772 (63.5%)	1,494 (53.4%)
A2	2,018 (26.8%)	860 (30.7%)
A3	729 (9.7%)	444 (15.9%)
GFR categories		
G3a	4,721 (62.8%)	
G3b	2,207 (29.4%)	2,207 (78.9%)
G4	591 (7.9%)	591 (21.1%)
CKD KDIGO classification		
Moderately increased risk	3,278 (43.6%)	
High risk	2,460 (32.7%)	1,302 (46.5%)
Very high risk	1,781 (23.7%)	1,496 (53.5%)
Serum Creatinine (mg/dL)		
Mean (SD)	1.4 (0.4)	1.7 (0.5)
Median (IQR)	1.3 (1.1 - 1.5)	1.6 (1.4 - 1.9)
Range	0.8 - 3.9	1.1 - 3.9
eGFR (ml/min/1.73m^2)		
Mean (SD)	46.2 (9.8)	35.7 (7.3)
Median (IQR)	48.7 (40.4 - 53.8)	37.3 (31.4 - 41.7)
Range	15.0 - 60.0	15.0 - 45.0
ACR (mg/g)		
Mean (SD)	248.6 (3,044.4)	334.1 (3,050.8)
Median (IQR)	14.6 (4.5 - 66.1)	26.0 (6.5 - 153.8)
Range	0.0 - 144,870.6	0.0 - 144,870.6
Urine Albumin (mg/ml)		
Mean (SD)	8.3 (28.3)	13.1 (36.3)
Median (IQR)	1.0 (0.3 - 4.0)	1.7 (0.4 - 10.1)
Range	0.0 - 658.0	0.0 - 658.0
Urine Creatinine (mg/dl)		
Mean (SD)	72.4 (47.5)	71.4 (47.0)
Median (IQR)	63.3 (41.3 - 86.0)	64.9 (43.3 - 85.0)
Range	0.1 - 722.1	0.7 - 722.1
Death at 2 years*	640 (8.5%)	358 (12.8%)
Outcome at 2 years		
Alive w/o Kidney Failure	6,842 (91.0%)	2,410 (86.1%)
Death w/o Kidney Failure	563 (7.5%)	300 (10.7%)
Kidney Failure	114 (1.5%)	88 (3.1%)

Death at 5 years*	1,539 (20.5%)	784 (28.0%)
Outcome at 5 years		
Alive w/o Kidney Failure	5,880 (78.2%)	1,933 (69.1%)
Death w/o Kidney Failure	1,400 (18.6%)	683 (24.4%)
Kidney Failure	239 (3.2%)	182 (6.5%)

795 SD: standard deviation, IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration
796 rate estimated by CKD-EPI formula
797 * Death after or before kidney failure
798
799

800

Table 2. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4.

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.96%	3.18%	2.36%	7.66%
Average observed risk (95% CI)	1.52% (1.24% to 1.79%)	3.37% (2.95% to 3.8%)	3.15% (2.5% to 3.79%)	6.86% (5.89% to 7.84%)
O/E ratio (95% CI)	1.57 (1.39 to 1.76)	1.06 (0.93 to 1.19)	1.33 (1.13 to 1.54)	0.9 (0.75 to 1.04)
Calibration intercept (95% CI)	0.18 (-0.1 to 0.45)	-0.26 (-0.45 to -0.07)	0.16 (-0.12 to 0.44)	-0.29 (-0.48 to -0.1)
Calibration slope (95% CI)	0.79 (0.61 to 0.96)	0.75 (0.65 to 0.86)	0.82 (0.6 to 1.03)	0.79 (0.66 to 0.92)
Discrimination				
C-index up to t-years (95% CI)	0.853 (0.812 to 0.892)	0.845 (0.818 to 0.872)	0.848 (0.803 to 0.885)	0.827 (0.796 to 0.857)
C/D AUC, at t years (95% CI)	0.855 (0.816 to 0.895)	0.847 (0.819 to 0.875)	0.853 (0.811 to 0.895)	0.836 (0.803 to 0.869)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C-index: truncated agreement index, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Figure 1. Study flowchart.

Figure 2. Cumulative incidence function curves for kidney failure (sky-blue line) and death before kidney failure (red line) in patients with (A) CKD stages 3a-3b-4 and (B) CKD stages 3b-4.

CKD: Chronic Kidney Disease.

Figure 3. Calibration curves for each group and prediction horizon.

The x-axis shows the risk predicted by the KFRE model, and the y-axis represents the observed risk estimated using the cumulative incidence function to consider the competing risk of death without kidney failure. CKD: Chronic Kidney Disease.

Section/Topic			Checklist Item	Page
Title and abstract				
Title	1	D;V	Identify the study as developing and/or validating a multivariable prediction model, the target population, and the outcome to be predicted.	1
Abstract	2	D;V	Provide a summary of objectives, study design, setting, participants, sample size, predictors, outcome, statistical analysis, results, and conclusions.	2
Introduction				
Background and objectives	3a	D;V	Explain the medical context (including whether diagnostic or prognostic) and rationale for developing or validating the multivariable prediction model, including references to existing models.	4-5
	3b	D;V	Specify the objectives, including whether the study describes the development or validation of the model or both.	5
Methods				
Source of data	4a	D;V	Describe the study design or source of data (e.g., randomized trial, cohort, or registry data), separately for the development and validation data sets, if applicable.	5
	4b	D;V	Specify the key study dates, including start of accrual; end of accrual; and, if applicable, end of follow-up.	5, 7
Participants	5a	D;V	Specify key elements of the study setting (e.g., primary care, secondary care, general population) including number and location of centres.	5
	5b	D;V	Describe eligibility criteria for participants.	5
	5c	D;V	Give details of treatments received, if relevant.	NA
Outcome	6a	D;V	Clearly define the outcome that is predicted by the prediction model, including how and when assessed.	7
	6b	D;V	Report any actions to blind assessment of the outcome to be predicted.	NA
Predictors	7a	D;V	Clearly define all predictors used in developing the multivariable prediction model, including how and when they were measured.	6
	7b	D;V	Report any actions to blind assessment of predictors for the outcome and other predictors.	NA
Sample size	8	D;V	Explain how the study size was arrived at.	6
Missing data	9	D;V	Describe how missing data were handled (e.g., complete-case analysis, single imputation, multiple imputation) with details of any imputation method.	9
Statistical analysis methods	10a	D	Describe how predictors were handled in the analyses.	NA
	10b	D	Specify type of model, all model-building procedures (including any predictor selection), and method for internal validation.	NA
	10c	V	For validation, describe how the predictions were calculated.	6-7
	10d	D;V	Specify all measures used to assess model performance and, if relevant, to compare multiple models.	8-9
	10e	V	Describe any model updating (e.g., recalibration) arising from the validation, if done.	NA
Risk groups	11	D;V	Provide details on how risk groups were created, if done.	NA
Development vs. validation	12	V	For validation, identify any differences from the development data in setting, eligibility criteria, outcome, and predictors.	Supplementary Material, Table S13 (page 17)
Results				
Participants	13a	D;V	Describe the flow of participants through the study, including the number of participants with and without the outcome and, if applicable, a summary of the follow-up time. A diagram may be helpful.	9
	13b	D;V	Describe the characteristics of the participants (basic demographics, clinical features, available predictors), including the number of participants with missing data for predictors and outcome.	9-10
	13c	V	For validation, show a comparison with the development data of the distribution of important variables (demographics, predictors and outcome).	Supplementary Material, Table S13 (page 17)
Model development	14a	D	Specify the number of participants and outcome events in each analysis.	NA
	14b	D	If done, report the unadjusted association between each candidate predictor and outcome.	NA
Model specification	15a	D	Present the full prediction model to allow predictions for individuals (i.e., all regression coefficients, and model intercept or baseline survival at a given time point).	NA
	15b	D	Explain how to use the prediction model.	NA
Model performance	16	D;V	Report performance measures (with CIs) for the prediction model.	10-12
Model-updating	17	V	If done, report the results from any model updating (i.e., model specification, model performance).	NA
Discussion				
Limitations	18	D;V	Discuss any limitations of the study (such as nonrepresentative sample, few events per predictor, missing data).	16-17
Interpretation	19a	V	For validation, discuss the results with reference to performance in the development data, and any other validation data.	13-15
	19b	D;V	Give an overall interpretation of the results, considering objectives, limitations, results from similar studies, and other relevant evidence.	13-18

Implications	20	D;V	Discuss the potential clinical use of the model and implications for future research.	17-18
Other information				
Supplementary information	21	D;V	Provide information about the availability of supplementary resources, such as study protocol, Web calculator, and data sets.	Supplementary PDF and Code in Github repo
Funding	22	D;V	Give the source of funding and the role of the funders for the present study.	19

*Items relevant only to the development of a prediction model are denoted by D, items relating solely to a validation of a prediction model are denoted by V, and items relating to both are denoted D;V. We recommend using the TRIPOD Checklist in conjunction with the TRIPOD Explanation and Elaboration document.

SUPPLEMENTARY MATERIAL

CONTENTS

1. SUPPLEMENTARY METHODS 34

1.1. KFRE equations validated externally by this study 34

Table S1. KFRE equations externally validated by the study 34

1.2. Variables 34

Table S2. Coding of variables 34

1.3. 2009 CKD Epidemiology Collaboration (CKD-EPI) formula for eGFR 34

2. SUPPLEMENTARY TABLES 35

Table S3. Baseline characteristics of study patients at CKD Stages 3a, 3b, or 4 for all predictors, stratified by 2- and 5-year outcomes. 35

Table S4. Baseline characteristics of study patients at CKD Stages 3b or 4 for all predictors, stratified by 2- and 5-year outcomes. 37

Table S5. Baseline characteristics and frequency of outcomes in the study population according to CKD stages. 39

Table S6. Distribution of CKD 3a-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network 41

Table S7. Distribution of CKD 3b-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network. 42

Table S8. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3a-3b-4. 43

Table S9. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3b-4. 44

Table S10. Summary of ACR, 2-year and 5-year predicted risks of kidney failure according to KFRE before and after winsorising the 1% and 99% extreme values of ACR. 45

Table S11. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4 following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE). 46

Table S12. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4, without considering competing risks. 47

Table S13. Comparisons of characteristics of original cohort that recalibrated Non North American version of KFRE and our study population 48

3. SUPPLEMENTARY FIGURES 49

Figure S1. Distribution of the 2-year and 5-year predicted risk estimated by KFRE equation according to kidney failure outcomes. 49

Figure S3. Distribution of ACR in CKD 3-4 and CKD 3b-4 patients before and after winsorising the 1% and 99% extreme values of ACR. 51

Figure S4. Distribution of the recalculated 2-year and 5-year predicted risk estimated by the KFRE equation after winsorising the 1% and 99% extreme values of ACR. 52

Figure S5. Calibration curves for each group and prediction horizon following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE). 53

Figure S6. Differences between Kaplan-Meier (KM) and cumulative incidence functions (CIF) estimates of the observed outcome risks in the presence of competing events, in CKD 3a-4 and CKD 3b-4 patients. 54

4. REFERENCES 55

1. SUPPLEMENTARY METHODS

1.1. KFRE equations validated externally by this study

This study performed external validation of the recalibrated equations for the non-North American population, which are available on page nine of the study supplementary material by *Tangri N, et al* (1) and were recommended as preferable by the article. These equations are implemented in the following web app: https://kidneyfailurerisk.com/. The equations we validated are shown in **Table S1**.

Table S1. KFRE equations externally validated by the study

Prediction horizons	Original regional equation calibrated for predicted risk of kidney failure
2-years	$1 - 0.9832^{e^{\left(-0.2201\times\left(\frac{age}{10}-7.036\right)+0.2467\times(male-0.5642)-0.5567\times\left(\frac{eGFR}{5}-7.222\right)+0.4510\times(\log(ACR)-5.137)\right)}}$
5-years	$1 - 0.9365^{e^{\left(-0.2201\times\left(\frac{age}{10}-7.036\right)+0.2467\times(male-0.5642)-0.5567\times\left(\frac{eGFR}{5}-7.222\right)+0.4510\times(\log(ACR)-5.137)\right)}}$

Source: Tangri N, et al. (1)

1.2. Variables

Table S2. Coding of variables

Variable	Coding
age	integer number that indicates the age in completed years
male	1 = male; 0 = female
eGFR_ckdepi	estimated glomerular filtration rate obtained by CKD-EPI formula in ml/min/1.73m^2
acr	albumin-to-creatinine ratio in mg/g

1.3. 2009 CKD Epidemiology Collaboration (CKD-EPI) formula for eGFR

$$eGFR = A \times (SCr/B)^C \times 0.993^{age} \times (1.159\ if\ black)$$

Where $A, B, and\ C$ are the following:

Female		Male	
$SCr \leq 0.7$	$A = 144$ $B = 0.7$ $C = -0.329$	$SCr \leq 0.9$	$A = 141$ $B = 0.9$ $C = -0.411$
$SCr > 0.7$	$A = 144$ $B = 0.7$ $C = -1.209$	$SCr > 0.9$	$A = 141$ $B = 0.9$ $C = -1.209$

2. SUPPLEMENTARY TABLES

Table S3. Baseline characteristics of study patients at CKD Stages 3a, 3b, or 4 for all predictors, stratified by 2- and 5-year outcomes.

	2-years		5-years	
Characteristic	**No kidney failure (n = 7,405)**	**Kidney failure (n = 114)**	**No kidney failure (n = 7,280)**	**Kidney failure (n = 239)**
Sex				
Female	4,062 (54.9%)	45 (39.5%)	4,015 (55.2%)	92 (38.5%)
Male	3,343 (45.1%)	69 (60.5%)	3,265 (44.8%)	147 (61.5%)
Age (years)				
Mean (SD)	74.1 (10.2)	66.6 (11.7)	74.2 (10.1)	66.5 (12.5)
Median (IQR)	75.0 (68.0, 81.0)	67.0 (59.2, 74.0)	75.0 (68.0, 82.0)	67.0 (59.0, 75.0)
Range	23.0, 97.0	36.0, 88.0	23.0, 97.0	26.0, 94.0
Hypertension	4,421 (59.7%)	65 (57.0%)	4,339 (59.6%)	147 (61.5%)
Diabetes Mellitus	1,796 (24.3%)	49 (43.0%)	1,743 (23.9%)	102 (42.7%)
Persistent albuminuria categories				
A1	4,749 (64.1%)	23 (20.2%)	4,725 (64.9%)	47 (19.7%)
A2	1,984 (26.8%)	34 (29.8%)	1,941 (26.7%)	77 (32.2%)
A3	672 (9.1%)	57 (50.0%)	614 (8.4%)	115 (48.1%)
GFR categories				
G3a	4,695 (63.4%)	26 (22.8%)	4,664 (64.1%)	57 (23.8%)
G3b	2,171 (29.3%)	36 (31.6%)	2,126 (29.2%)	81 (33.9%)
G4	539 (7.3%)	52 (45.6%)	490 (6.7%)	101 (42.3%)
CKD KDIGO classification				
Moderately increased risk	3,266 (44.1%)	12 (10.5%)	3,256 (44.7%)	22 (9.2%)
High risk	2,448 (33.1%)	12 (10.5%)	2,429 (33.4%)	31 (13.0%)
Very high risk	1,691 (22.8%)	90 (78.9%)	1,595 (21.9%)	186 (77.8%)
Serum Creatinine (mg/dL)				
Mean (SD)	1.4 (0.4)	2.0 (0.7)	1.3 (0.4)	2.0 (0.7)
Median (IQR)	1.3 (1.1, 1.5)	1.9 (1.5, 2.5)	1.3 (1.1, 1.5)	1.9 (1.5, 2.4)
Range	0.8, 3.8	1.0, 3.9	0.8, 3.8	0.9, 3.9

eGFR (ml/min/1.73m2)				
Mean (SD)	46.4 (9.6)	33.7 (12.5)	46.6 (9.4)	34.5 (12.4)
Median (IQR)	48.9 (40.8, 53.9)	31.7 (23.2, 42.8)	49.0 (41.1, 53.9)	33.0 (23.5, 44.2)
Range	15.0, 60.0	15.4, 59.8	15.1, 60.0	15.0, 59.8
ACR (mg/g)				
Mean (SD)	235.5 (3,059.4)	1,101.7 (1,614.1)	229.3 (3,083.4)	836.1 (1,283.1)
Median (IQR)	14.2 (4.4, 62.7)	302.0 (52.5, 1,663.9)	14.0 (4.4, 59.4)	270.9 (51.2, 992.4)
Range	0.0, 144,870.6	2.5, 7,462.7	0.0, 144,870.6	0.2, 7,462.7
Urine Albumin (mg/ml)				
Mean (SD)	7.6 (26.5)	52.1 (73.5)	7.1 (25.7)	44.0 (62.3)
Median (IQR)	0.9 (0.3, 3.7)	16.0 (4.3, 71.6)	0.9 (0.3, 3.5)	15.3 (3.4, 56.5)
Range	0.0, 658.0	0.2, 348.1	0.0, 658.0	0.0, 348.1
Urine Creatinine (mg/dl)				
Mean (SD)	72.5 (47.7)	64.8 (33.7)	72.4 (47.0)	69.8 (61.0)
Median (IQR)	63.4 (41.4, 86.5)	59.6 (39.6, 85.0)	63.5 (41.3, 86.6)	58.7 (41.0, 85.0)
Range	0.1, 722.1	6.4, 218.6	0.1, 620.1	6.4, 722.1
Death at 2 years*	563 (7.6%)	77 (67.5%)	563 (7.7%)	77 (32.2%)
Outcome at 2 years				
Alive w/o Kidney Failure	6,842 (92.4%)	0 (0.0%)	6,717 (92.3%)	125 (52.3%)
Death w/o Kidney Failure	563 (7.6%)	0 (0.0%)	563 (7.7%)	0 (0.0%)
Kidney Failure	0 (0.0%)	114 (100.0%)	0 (0.0%)	114 (47.7%)
Death at 5 years*	1,462 (19.7%)	77 (67.5%)	1,400 (19.2%)	139 (58.2%)
Outcome at 5 years				
Alive w/o Kidney Failure	5,880 (79.4%)	0 (0.0%)	5,880 (80.8%)	0 (0.0%)
Death w/o Kidney Failure	1,400 (18.9%)	0 (0.0%)	1,400 (19.2%)	0 (0.0%)
Kidney Failure	125 (1.7%)	114 (100.0%)	0 (0.0%)	239 (100.0%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula

* Death after or before kidney failure

Table S4. Baseline characteristics of study patients at CKD Stages 3b or 4 for all predictors, stratified by 2- and 5-year outcomes.

	2-years		5-years	
Characteristic	**No kidney failure (n = 2,710)**	**Kidney failure (n = 88)**	**No kidney failure (n = 2,616)**	**Kidney failure (n = 182)**
Sex				
Female	1,363 (50.3%)	35 (39.8%)	1,329 (50.8%)	69 (37.9%)
Male	1,347 (49.7%)	53 (60.2%)	1,287 (49.2%)	113 (62.1%)
Age (years)				
Mean (SD)	75.9 (10.4)	66.1 (12.1)	76.2 (10.2)	66.9 (12.4)
Median (IQR)	77.0 (70.0, 83.0)	67.0 (59.0, 74.0)	77.0 (70.0, 83.0)	67.0 (59.2, 75.0)
Range	23.0, 97.0	36.0, 88.0	23.0, 97.0	26.0, 94.0
Hypertension	1,581 (58.3%)	55 (62.5%)	1,517 (58.0%)	119 (65.4%)
Diabetes Mellitus	635 (23.4%)	39 (44.3%)	596 (22.8%)	78 (42.9%)
Persistent albuminuria categories				
A1	1,483 (54.7%)	11 (12.5%)	1,469 (56.2%)	25 (13.7%)
A2	830 (30.6%)	30 (34.1%)	798 (30.5%)	62 (34.1%)
A3	397 (14.6%)	47 (53.4%)	349 (13.3%)	95 (52.2%)
GFR categories				
G3a	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
G3b	2,171 (80.1%)	36 (40.9%)	2,126 (81.3%)	81 (44.5%)
G4	539 (19.9%)	52 (59.1%)	490 (18.7%)	101 (55.5%)
CKD KDIGO classification				
Moderately increased risk	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
High risk	1,294 (47.7%)	8 (9.1%)	1,286 (49.2%)	16 (8.8%)
Very high risk	1,416 (52.3%)	80 (90.9%)	1,330 (50.8%)	166 (91.2%)
Serum Creatinine (mg/dL)				
Mean (SD)	1.7 (0.4)	2.3 (0.6)	1.7 (0.4)	2.2 (0.6)
Median (IQR)	1.6 (1.4, 1.9)	2.1 (1.8, 2.5)	1.6 (1.4, 1.8)	2.1 (1.7, 2.5)
Range	1.1, 3.8	1.2, 3.9	1.1, 3.8	1.2, 3.9
eGFR (ml/min/1.73m^2)				
Mean (SD)	35.9 (7.1)	28.2 (8.1)	36.1 (7.0)	29.0 (8.3)
Median (IQR)	37.6 (31.8, 41.8)	26.9 (21.6, 34.9)	37.8 (32.1, 41.9)	28.3 (22.4, 35.4)
Range	15.0, 45.0	15.4, 43.8	15.1, 45.0	15.0, 44.9
ACR (mg/g)				
Mean (SD)	306.8 (3,082.4)	1,172.8 (1,631.1)	296.0 (3,133.9)	881.4 (1,272.2)
Median (IQR)	24.6 (6.3, 145.4)	367.7 (149.1, 1,811.8)	23.3 (6.1, 131.2)	334.6 (143.8, 1,076.5)

Range	0.0, 144,870.6	2.5, 7,462.7	0.0, 144,870.6	1.4, 7,462.7
Urine Albumin (mg/ml)				
Mean (SD)	11.7 (33.3)	56.1 (77.1)	10.7 (32.2)	47.4 (64.4)
Median (IQR)	1.5 (0.4, 8.7)	16.3 (8.9, 66.6)	1.4 (0.4, 7.7)	16.5 (8.6, 60.3)
Range	0.0, 658.0	0.2, 348.1	0.0, 658.0	0.1, 348.1
Urine Creatinine (mg/dl)				
Mean (SD)	71.7 (47.4)	62.1 (33.5)	71.7 (45.8)	68.3 (61.8)
Median (IQR)	65.1 (43.7, 85.0)	55.3 (38.1, 85.0)	65.4 (43.9, 85.0)	58.0 (40.1, 85.0)
Range	0.7, 722.1	6.4, 218.6	0.7, 620.1	6.4, 722.1
Death at 2 years*	300 (11.1%)	58 (65.9%)	300 (11.5%)	58 (31.9%)
Outcome at 2 years				
Alive w/o Kidney Failure	2,410 (88.9%)	NA	2,316 (88.5%)	94 (51.6%)
Death w/o Kidney Failure	300 (11.1%)	NA	300 (11.5%)	NA
Kidney Failure	NA	88 (100.0%)	NA	88 (48.4%)
Death at 5 years*	726 (26.8%)	58 (65.9%)	683 (26.1%)	101 (55.5%)
Outcome at 5 years				
Alive w/o Kidney Failure	1,933 (71.3%)	0 (0.0%)	1,933 (73.9%)	0 (0.0%)
Death w/o Kidney Failure	683 (25.2%)	0 (0.0%)	683 (26.1%)	NA
Kidney Failure	94 (3.5%)	88 (100.0%)	NA	182 (100.0%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula. NA: not applicable

* Death after or before kidney failure

Table S5. Baseline characteristics and frequency of outcomes in the study population according to CKD stages.

Characteristic	G3a (n = 4,721)	G3b (n = 2,207)	G4 (n = 591)
Sex			
Female	2,709 (57.4%)	1,102 (49.9%)	296 (50.1%)
Male	2,012 (42.6%)	1,105 (50.1%)	295 (49.9%)
Age (years)			
Mean (SD)	73.1 (9.9)	76.0 (10.2)	73.9 (11.8)
Median (IQR)	74.0 (67.0 - 80.0)	77.0 (70.0 - 83.0)	75.0 (67.0 - 83.0)
Range	23.0 - 97.0	26.0 - 97.0	23.0 - 95.0
Hypertension	2,850 (60.4%)	1,295 (58.7%)	341 (57.7%)
Diabetes Mellitus	1,171 (24.8%)	521 (23.6%)	153 (25.9%)
Persistent albuminuria categories			
A1	3,278 (69.4%)	1,302 (59.0%)	192 (32.5%)
A2	1,158 (24.5%)	632 (28.6%)	228 (38.6%)
A3	285 (6.0%)	273 (12.4%)	171 (28.9%)
CKD KDIGO classification			
Moderately increased risk	3,278 (69.4%)	0 (0.0%)	0 (0.0%)
High risk	1,158 (24.5%)	1,302 (59.0%)	0 (0.0%)
Very high risk	285 (6.0%)	905 (41.0%)	591 (100.0%)
Serum Creatinine (mg/dL)			
Mean (SD)	1.2 (0.2)	1.5 (0.2)	2.3 (0.5)
Median (IQR)	1.1 (1.0 - 1.3)	1.5 (1.3 - 1.7)	2.3 (1.9 - 2.6)
Range	0.8 - 1.9	1.1 - 2.4	1.5 - 3.9
eGFR (ml/min/1.73m^2)			
Mean (SD)	52.5 (3.9)	38.8 (4.2)	24.2 (4.1)
Median (IQR)	52.6 (49.4 - 55.6)	39.3 (35.3 - 42.4)	24.7 (21.2 - 27.7)
Range	45.0 - 60.0	30.0 - 45.0	15.0 - 30.0
ACR (mg/g)			
Mean (SD)	198.0 (3,039.8)	302.6 (3,386.3)	451.7 (1,109.7)
Median (IQR)	10.8 (3.9 - 41.5)	20.3 (5.3 - 100.1)	127.2 (17.7 - 405.2)
Range	0.0 - 137,672.1	0.0 - 144,870.6	0.1 - 18,259.2
Urine Albumin (mg/ml)			
Mean (SD)	5.5 (21.8)	10.0 (31.4)	25.0 (48.8)
Median (IQR)	0.7 (0.2 - 2.4)	1.3 (0.3 - 5.8)	7.4 (1.3 - 20.9)
Range	0.0 - 548.0	0.0 - 658.0	0.0 - 383.0
Urine Creatinine (mg/dl)			
Mean (SD)	72.9 (47.9)	71.3 (46.0)	72.0 (50.7)
Median (IQR)	62.4 (40.4 - 88.1)	64.8 (43.0 - 85.0)	65.3 (44.6 - 85.0)
Range	0.1 - 438.3	0.8 - 620.1	0.7 - 722.1
Death at 2 years*	282 (6.0%)	230 (10.4%)	128 (21.7%)
Outcome at 2 years			
Alive w/o Kidney Failure	4,432 (93.9%)	1,965 (89.0%)	445 (75.3%)

Death w/o Kidney Failure	263 (5.6%)	206 (9.3%)	94 (15.9%)
Kidney Failure	26 (0.6%)	36 (1.6%)	52 (8.8%)
Death at 5 years*	755 (16.0%)	555 (25.1%)	229 (38.7%)
Outcome at 5 years			
Alive w/o Kidney Failure	3,947 (83.6%)	1,622 (73.5%)	311 (52.6%)
Death w/o Kidney Failure	717 (15.2%)	504 (22.8%)	179 (30.3%)
Kidney Failure	57 (1.2%)	81 (3.7%)	101 (17.1%)

IQR: interquartile range, ACR: urine albumin to creatinine ratio, eGFR: glomerular filtration rate estimated by CKD-EPI formula

* Death after or before kidney failure

Table S6. Distribution of CKD 3a-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network

		Outcome		
Healthcare center*	**Overall (n = 7,519)**	**Alive w/o Kidney Failure (n = 5,880)**	**Death w/o Kidney Failure (n = 1,400)**	**Kidney Failure (n = 239)**
Healthcare №1	74 (100.0%)	48 (64.9%)	18 (24.3%)	8 (10.8%)
Healthcare №2	58 (100.0%)	52 (89.7%)	6 (10.3%)	0 (0.0%)
Healthcare №3	403 (100.0%)	319 (79.2%)	73 (18.1%)	11 (2.7%)
Healthcare №4	287 (100.0%)	204 (71.1%)	71 (24.7%)	12 (4.2%)
Healthcare №5	308 (100.0%)	242 (78.6%)	53 (17.2%)	13 (4.2%)
Healthcare №6	1,471 (100.0%)	1,088 (74.0%)	298 (20.3%)	85 (5.8%)
Healthcare №7	34 (100.0%)	20 (58.8%)	11 (32.4%)	3 (8.8%)
Healthcare №8	1,032 (100.0%)	858 (83.1%)	160 (15.5%)	14 (1.4%)
Healthcare №9	207 (100.0%)	158 (76.3%)	42 (20.3%)	7 (3.4%)
Healthcare №10	258 (100.0%)	179 (69.4%)	73 (28.3%)	6 (2.3%)
Healthcare №11	77 (100.0%)	71 (92.2%)	5 (6.5%)	1 (1.3%)
Healthcare №12	1,289 (100.0%)	1,058 (82.1%)	202 (15.7%)	29 (2.2%)
Healthcare №13	679 (100.0%)	497 (73.2%)	166 (24.4%)	16 (2.4%)
Healthcare №14	752 (100.0%)	586 (77.9%)	143 (19.0%)	23 (3.1%)
Healthcare №15	454 (100.0%)	381 (83.9%)	64 (14.1%)	9 (2.0%)
Healthcare №16	102 (100.0%)	90 (88.2%)	10 (9.8%)	2 (2.0%)
Healthcare №17	34 (100.0%)	29 (85.3%)	5 (14.7%)	0 (0.0%)

* For privacy reasons, the name of the current healthcare provider is not disclosed. However, we can provide the names internally if the request is reasonable and appropriate mechanisms are in place to ensure the protection of data privacy.

Table S7. Distribution of CKD 3b-4 patients included in the analysis across 17 health facilities of the EsSalud Rebagliati Network.

		Outcome		
Healthcare center*	**Overall (n = 2,798)**	**Alive w/o Kidney Failure (n = 1,933)**	**Death w/o Kidney Failure (n = 683)**	**Kidney Failure (n = 182)**
Healthcare №1	26 (100.0%)	10 (38.5%)	10 (38.5%)	6 (23.1%)
Healthcare №2	12 (100.0%)	8 (66.7%)	4 (33.3%)	0 (0.0%)
Healthcare №3	129 (100.0%)	87 (67.4%)	32 (24.8%)	10 (7.8%)
Healthcare №4	113 (100.0%)	68 (60.2%)	35 (31.0%)	10 (8.8%)
Healthcare №5	115 (100.0%)	81 (70.4%)	24 (20.9%)	10 (8.7%)
Healthcare №6	921 (100.0%)	644 (69.9%)	212 (23.0%)	65 (7.1%)
Healthcare №7	22 (100.0%)	11 (50.0%)	8 (36.4%)	3 (13.6%)
Healthcare №8	271 (100.0%)	194 (71.6%)	67 (24.7%)	10 (3.7%)
Healthcare №9	70 (100.0%)	47 (67.1%)	17 (24.3%)	6 (8.6%)
Healthcare №10	90 (100.0%)	59 (65.6%)	28 (31.1%)	3 (3.3%)
Healthcare №11	15 (100.0%)	13 (86.7%)	1 (6.7%)	1 (6.7%)
Healthcare №12	408 (100.0%)	294 (72.1%)	93 (22.8%)	21 (5.1%)
Healthcare №13	216 (100.0%)	134 (62.0%)	70 (32.4%)	12 (5.6%)
Healthcare №14	215 (100.0%)	152 (70.7%)	47 (21.9%)	16 (7.4%)
Healthcare №15	144 (100.0%)	106 (73.6%)	30 (20.8%)	8 (5.6%)
Healthcare №16	23 (100.0%)	18 (78.3%)	4 (17.4%)	1 (4.3%)
Healthcare №17	8 (100.0%)	7 (87.5%)	1 (12.5%)	0 (0.0%)

* For privacy reasons, the name of the current healthcare provider is not disclosed. However, we can provide the names internally if the request is reasonable and appropriate mechanisms are in place to ensure the protection of data privacy.

Table S8. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3a-3b-4.

Year	Kidney failure		Death without kidney failure	
	%	95% CI	%	95% CI
1-year	0.68%	(0.49% to 0.86%)	3.82%	(3.38% to 4.25%)
2-year	1.52%	(1.24% to 1.79%)	7.49%	(6.89% to 8.08%)
3-year	2.23%	(1.9% to 2.57%)	11.2%	(10.48% to 11.91%)
4-year	2.88%	(2.5% to 3.26%)	15.58%	(14.75% to 16.41%)
5-year	3.37%	(2.95% to 3.8%)	20.46%	(19.48% to 21.42%)

%: observed risk estimated utilising the cumulative incidence function with the Aalen-Johansen estimator to account for competing risk; CI: confidence interval

Table S9. Cumulative incidence of kidney failure and death without kidney failure in patients with CKD stages 3b-4.

Year	Kidney failure		Death without kidney failure	
	%	95% CI	%	95% CI
1-year	1.54%	(1.08% to 1.99%)	6%	(5.12% to 6.88%)
2-year	3.15%	(2.5% to 3.79%)	10.72%	(9.57% to 11.86%)
3-year	4.72%	(3.93% to 5.5%)	15.51%	(14.16% to 16.84%)
4-year	6.02%	(5.12% to 6.9%)	21.03%	(19.48% to 22.55%)
5-year	6.86%	(5.89% to 7.83%)	26.59%	(24.84% to 28.3%)

%: observed risk estimated utilising the cumulative incidence function with the Aalen-Johansen estimator to account for competing risk; CI: confidence interval; CI: confidence interval

Table S10. Summary of ACR, 2-year and 5-year predicted risks of kidney failure according to KFRE before and after winsorising the 1% and 99% extreme values of ACR.

	Original data	Winsorised outliers in ACR.
Characteristic	**N = 7,519**	**N = 7,519**
ACR (mg/g)		
Mean ± SD	248.620 ± 3,044.427	144.053 ± 437.405
Median (IQR)	14.634 (4.484, 66.114)	14.634 (4.484, 66.114)
Range	0.002, 144,870.588	0.236, 3,195.727
Predicted risk of kidney failure to 2 years (%)		
Mean ± SD	0.963 ± 3.263	0.944 ± 3.155
Median (IQR)	0.131 (0.057, 0.429)	0.131 (0.057, 0.429)
Range	0.001, 53.657	0.006, 53.657
Predicted risk of kidney failure to 5 years (%)		
Mean ± SD	3.182 ± 8.913	3.138 ± 8.760
Median (IQR)	0.507 (0.220, 1.650)	0.508 (0.221, 1.649)
Range	0.004, 94.911	0.024, 94.911

SD: standard deviation, IQR: interquartile range, ACR: urine albumin to creatinine ratio

Table S11. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4 following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE).

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.94%	3.14%	2.32%	7.58%
Average observed proportion (95% CI)	1.52% (1.24% to 1.79%)	3.37% (2.95% to 3.8%)	3.15% (2.5% to 3.79%)	6.86% (5.89% to 7.84%)
O/E ratio (95% CI)	1.61 (1.42 to 1.79)	1.08 (0.95 to 1.2)	1.35 (1.15 to 1.56)	0.91 (0.76 to 1.05)
Calibration intercept (95% CI)	0.21 (-0.06 to 0.49)	-0.23 (-0.41 to -0.04)	0.19 (-0.09 to 0.47)	-0.26 (-0.45 to -0.07)
Calibration slope (95% CI)	0.79 (0.61 to 0.97)	0.77 (0.66 to 0.87)	0.82 (0.61 to 1.04)	0.8 (0.67 to 0.94)
Discrimination				
C-index up to t-years (95% CI)	0.853 (0.812 to 0.893)	0.845 (0.818 to 0.872)	0.848 (0.804 to 0.885)	0.828 (0.797 to 0.857)
C/D AUC, at t years (95% CI)	0.855 (0.816 to 0.895)	0.848 (0.82 to 0.875)	0.854 (0.812 to 0.896)	0.837 (0.804 to 0.87)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C-index: truncated agreement index, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Table S12. Performance measures of KFRE in the external dataset of patients with CKD stages 3a-3b-4 and 3b-4, without considering competing risks.

Validation aspect and performance measure	CKD Stages 3a-3b-4		CKD Stages 3b-4	
	t = 2 year	t = 5 year	t = 2 year	t = 5 year
Calibration				
Average predicted risk	0.96%	3.18%	2.36%	7.66%
Average observed proportion	1.58%	3.72%	3.35%	7.88%
O/E ratio (95% CI)	1.64 (1.37 to 1.97)	1.17 (1.03 to 1.33)	1.42 (1.15 to 1.75)	1.03 (0.89 to 1.19)
Calibration slope (95% CI)	0.79 (0.72 to 0.85)	0.79 (0.72 to 0.85)	0.83 (0.74 to 0.93)	0.83 (0.74 to 0.93)
Discrimination				
Harrell C (95% CI)	0.856 (0.817 to 0.895)	0.856 (0.83 to 0.883)	0.85 (0.809 to 0.891)	0.839 (0.809 to 0.869)
Uno C (95% CI)	0.856 (0.817 to 0.895)	0.851 (0.825 to 0.878)	0.851 (0.81 to 0.892)	0.832 (0.801 to 0.864)
C/D AUC, at t years (95% CI)	0.861 (0.822 to 0.9)	0.86 (0.832 to 0.887)	0.86 (0.818 to 0.901)	0.846 (0.812 to 0.879)

CKD: chronic kidney disease, t: time, O/E: Observed versus expected outcome ratio %: percentage, 95%CI: 95% confidence interval, C/D AUC-td: area under ROC curves time dependent on cumulative sensitivity and dynamic specificity.

Table S13. Comparisons of characteristics of original cohort that recalibrated Non North American version of KFRE and our study population

		Current study	
Characteristics	**Original Study (Non-North American population)**	**CKD Stages 3a-4**	**CKD Stages 3b-4**
Numbef of participants	103753	7519	2798
F/U Time, years, Median (IQR)	4 (3, 6)	4.9 (3.5, 5.9)	4.6 (3.2, 5.8)
Age, years (SD)	71 (12)	74 (10.2)	75.6 (10.6)
Male, n (%)	46632 (45%)	3412 (45.4%)	1400 (50%)
Black ethnicity, n (%)	393 (0.4%)	0 (0%)	0 (0%)
eGFR, ml/min/1.73m^2 (SD)	47 (12)	46.2 (9.8)	35.7 (7.3)
Albuminuria, n (%)	24962 (34%)	2747 (36.5%)	1304 (46.6%)
Kidney Failure Incidence (per 1000 py)	9.2	7.4	16.1

F/U: follow-up; eGFR: glomerular filtration rate estimated by CKD-EPI formula

3. SUPPLEMENTARY FIGURES



Figure S1. Distribution of the 2-year and 5-year predicted risk estimated by KFRE equation according to kidney failure outcomes.



Figure S2. Distribution of the four KFRE equation variables in CKD 3-4 and CKD 3b-4 patients.

(A) age in years, (B) estimated glomerular filtration rate (eGFR) according to the CKD-EPI formula, (C) urine albumin to creatinine ratio (ACR) expressed in the original scale, and (D) natural logarithm scale for improved comparison of distributions.



Figure S3. Distribution of ACR in CKD 3-4 and CKD 3b-4 patients before and after winsorising the 1% and 99% extreme values of ACR.



Figure S4. Distribution of the recalculated 2-year and 5-year predicted risk estimated by the KFRE equation after winsorising the 1% and 99% extreme values of ACR.



Figure S5. Calibration curves for each group and prediction horizon following the application of winsorisation to the ACR variable and the subsequent recalculation of predicted risks using the Kidney Failure Risk Equation (KFRE).



Figure S6. Differences between Kaplan-Meier (KM) and cumulative incidence functions (CIF) estimates of the observed outcome risks in the presence of competing events, in CKD 3a-4 and CKD 3b-4 patients.



Figure S7. Calibration curves for each group and prediction horizon, disregarding competing risks.

4. REFERENCES

1. Tangri N, Grams ME, Levey AS, Coresh J, Appel LJ, Astor BC, et al. Multinational Assessment of Accuracy of Equations for Predicting Risk of Kidney Failure: A Meta-analysis. JAMA [Internet]. 12 de enero de 2016 [citado 30 de enero de 2020];315(2):164-74. Disponible en: https://jamanetwork.com/journals/jama/fullarticle/2481005


Total patients in VISARE database
(n = 57,308)
34,564 screened patients did not CKD in any stage
Total of patients with CKD
(n = 22,744)
Not elegible (n = 15,225)
8,426 lacks of data on urine albumin and urine creatinin
6,799 were in other CKD stages (1, 2, or 5)
Patients with CKD 3a-4
(n = 7,519)
Patients with CKD 3b-4
(n = 2,798)


A CKD Stages 3a-3b-4
Death w/o Kidney Failure
Kidney Failure
Cumulative incidence
100%
75%
50%
25%
0%
4%
3%
2%
1%
0%
0
1
2
3
4
5
Years
Number at risk (number of events)
7519 (0)
7181 (338)
6842 (677)
6509 (1010)
4893 (1349)
3549 (1639


B CKD Stages 3b-4
Death w/o Kidney Failure
Kidney Failure
Cumulative incidence
100%
75%
50%
25%
0%
8%
6%
4%
2%
0%
0
1
2
3
4
5
Years
Number at risk (number of events)
2798 (0)
2587 (211)
2410 (388)
2232 (566)
1595 (736)
1161 (865


A
CKD Stages 3a-3b-4
(2 year KFRE)
B
CKD Stages 3a-3b-4
(5 year KFRE)
C
CKD Stages 3b-4
(2 year KFRE)
D
CKD Stages 3b-4
(5 year KFRE)
Observed outcome proportions
Predicted risks
0.0
0.2
0.4
0.6
0.8
1.0